These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 35681538)

  • 21. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
    Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
    JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells.
    Cromer MK; Camarena J; Martin RM; Lesch BJ; Vakulskas CA; Bode NM; Kurgan G; Collingwood MA; Rettig GR; Behlke MA; Lemgart VT; Zhang Y; Goyal A; Zhao F; Ponce E; Srifa W; Bak RO; Uchida N; Majeti R; Sheehan VA; Tisdale JF; Dever DP; Porteus MH
    Nat Med; 2021 Apr; 27(4):677-687. PubMed ID: 33737751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
    Segura EER; Ayoub PG; Hart KL; Kohn DB
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
    Persons DA
    Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease.
    Leonard A; Tisdale JF; Bonner M
    Hematol Oncol Clin North Am; 2022 Aug; 36(4):769-795. PubMed ID: 35773052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic-Stem-Cell-Targeted Gene-Addition and Gene-Editing Strategies for β-hemoglobinopathies.
    Drysdale CM; Nassehi T; Gamer J; Yapundich M; Tisdale JF; Uchida N
    Cell Stem Cell; 2021 Feb; 28(2):191-208. PubMed ID: 33545079
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells.
    Moiani A; Letort G; Lizot S; Chalumeau A; Foray C; Felix T; Le Clerre D; Temburni-Blake S; Hong P; Leduc S; Pinard N; Marechal A; Seclen E; Boyne A; Mayer L; Hong R; Pulicani S; Galetto R; Gouble A; Cavazzana M; Juillerat A; Miccio A; Duclert A; Duchateau P; Valton J
    Nat Commun; 2024 Jun; 15(1):4965. PubMed ID: 38862518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
    Dong AC; Rivella S
    Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
    Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
    PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.
    Uchida N; Hsieh MM; Raines L; Haro-Mora JJ; Demirci S; Bonifacino AC; Krouse AE; Metzger ME; Donahue RE; Tisdale JF
    Nat Commun; 2019 Oct; 10(1):4479. PubMed ID: 31578323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
    Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
    Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease.
    Justus DG; Manis JP
    Transfus Apher Sci; 2021 Feb; 60(1):103059. PubMed ID: 33541761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia.
    Lu D; Gong X; Guo X; Chen Y; Zhu Y; Fang Y; Cai Q; Xu M; Yang H; Li D; Zeng Y; Zeng F
    Stem Cells; 2024 Mar; 42(3):278-289. PubMed ID: 38134938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease.
    Ramadier S; Chalumeau A; Felix T; Othman N; Aknoun S; Casini A; Maule G; Masson C; De Cian A; Frati G; Brusson M; Concordet JP; Cavazzana M; Cereseto A; El Nemer W; Amendola M; Wattellier B; Meneghini V; Miccio A
    Mol Ther; 2022 Jan; 30(1):145-163. PubMed ID: 34418541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.
    Srivastava A; Shaji RV
    Haematologica; 2017 Feb; 102(2):214-223. PubMed ID: 27909215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene Therapy and Genome Editing.
    Boulad F; Mansilla-Soto J; Cabriolu A; Rivière I; Sadelain M
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):329-342. PubMed ID: 29458735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective therapies for sickle cell disease: are we there yet?
    Crossley M; Christakopoulos GE; Weiss MJ
    Trends Genet; 2022 Dec; 38(12):1284-1298. PubMed ID: 35934593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.